Safety of sorafenib (SOR) dose in United States (US) patients (pts) with advanced hepatocellular carcinoma (HCC) with varying liver dysfunction: Lessons from a Hispanic-rich South Texas institution

Authors :: Raed Al-Rajabi
Norma S. Ketchum
Joel E. Michalek
Devalingam Mahalingam
Ting-Wei Lu
Sukeshi R. Patel
Source :: Journal of Clinical Oncology. 33:e15150-e15150
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: e15150 Background: HCC pts often present with Child Pugh (CP) B liver dysfunction but are poorly represented in trials. GIDEON showed median dose (duration) was 742 mg (17.6 weeks) in CP A vs 677 m...

Subjects :: Sorafenib
Cancer Research
medicine.medical_specialty
Pediatrics
business.industry
medicine.disease
Gastroenterology
digestive system diseases
Oncology
Internal medicine
Hepatocellular carcinoma
medicine
Liver dysfunction
business
medicine.drug

Tools